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Summary: Seven hundred and four HIV-1/2-positive, antiretroviral therapy (ART) naı ¨ve patients were screened for HTLV-1
infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients. Each co-infected individual was matched with two HIV
mono-infected patients according to World Health Organization clinical stage, age +5 years and gender. Key clinical and laboratory
characteristics were compared between the two groups. Mono-infected and co-infected patients displayed similar clinical
characteristics. However, co-infected patients had higher absolute CD4þ T-cell counts (P ¼ 0.001), higher percentage CD4þ T-cell
counts (P , 0.001) and higher CD4/CD8 ratios (P , 0.001). Although HIV plasma RNAviral loads were inversely correlated with CD4þ
T-cell-counts in mono-infected patients (P, 0.0001), a correlation was not found in co-infected individuals (P ¼ 0.11). Patients with
untreated HIV and HTLV-1 co-infection show a dissociation between immunological and HIV virological markers. Current
recommendations for initiating ART and chemoprophylaxis against opportunistic infections in resource-poor settings rely on more
readily available CD4þ T-cell counts without viral load parameters. These guidelines are not appropriate for co-infected individuals in
whom high CD4þ T-cell counts persist despite high HIV viral load states. Thus, for co-infected patients, even in resource-poor
settings, HIV viral loads are likely to contribute information crucial for the appropriate timing of ART introduction.
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INTRODUCTION
Human T-cell lymphotropic virus type 1 (HTLV-1) and human
immunodeﬁciency virus type 1/2 (HIV-1/2) are genetically and
functionally distinct retroviruses that target CD4þ Tl y m p h o -
cytes through different surface receptors. HTLV-1 is frequently
associated with lymphocytosis, although malignant transforma-
tion of infected cells, producing acute or chronic T-cell leukae-
mia/lymphoma, is much less common.
1 In contrast, HIV
infection causes shortened survival time and impaired pro-
duction of CD4þ T-cells, with a progressive decline of this cell
population in the peripheral blood.
2
More than 50% of the global HIV-infected population, and
around 72% (or 4.7 million) of individuals in need of antiretro-
viral (ARV) therapy live in sub-Saharan Africa, a region that
also bears a signiﬁcant burden of HTLV-1 infection.
3,4 In
2007, only one in four people in need of treatment in this
region was on ARV therapy.
3 In Mozambique, a country with
19 million inhabitants, the prevalence of HIV infection in
adults is estimated to be 16.0%. In October 2008, an estimated
489,000 patients were being followed in HIV outpatient clinics
in Mozambique. Of the 430,000 people who were in need
of ARV drugs throughout the country, only about 121,000
were initiated on this therapy by October 2008 (Source of
Information: Medical Assistance Department, Ministry of Health,
Mozambique). ARV therapy initiation in Mozambique is primar-
ily guided by the CD4þ T-cell count and by the HIV clinical
stage on the basis that CD4þ T-cell count is considered to be
a reliable and available parameter to guide decision-making
during management of HIV infection,
5,6 whereas HIV viral
load monitoring is generally unavailable throughout the
country.
The basis of the heterogeneous geographical and demo-
graphic distribution of HTLV-1 in Africa is not well understood.
In southern and central Africa, the prevalence of HTLV-1 infec-
tion has been reported to range between 0.5% and 7.1%,
7–13
peaking in groups reporting high rates of sexual activity and
in HIV-infected individuals,
14–19 and in this population
sexual transmission of HTLV-1 is thought to be a dominant
mode of acquisition. With the HIV/AIDS epidemic on the
rise, it is foreseeable that individuals co-infected with HIV
and HTLV-1 will be frequently seen at HIV treatment and
care centres.
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Africa, little data are available about the clinical presentation
of co-infected individuals in the region. Studies in other
regions, including South American, show that in co-infected
patients clinical progression of HIV infection occurs despite
normal or high CD4þ T-cell counts.
20–22 These apparently
paradoxical ﬁndings are of a even greater relevance in the
context of the scaling-up of ARV therapy programmes through-
out sub-Saharan Africa as CD4 cell levels are the dominant
criterion for timing institution of antiretroviral therapy (ART).
Against this background, we investigated the clinical and
laboratory characteristics of HIV-infected patients with
HTLV-1 co-infection in Maputo, Mozambique.
METHODS
Study design
A nested case-control study was designed to enrol HIV positive
patients presenting to an HIV Outpatient Clinic (HOP) for their
clinical assessment after an HIV screening test. HIV-positive
patients co-infected with HTLV-1 (co-infected patients) were
deﬁned as cases and HIV-positive patients without co-infection
with HTLV-1 (mono-infected patients) were considered to be
controls allowing assessment of the impact of HTLV-1 superim-
posed on HIV-1 infection.
This study was approved by the National Health Bioethics
Committee in Mozambique and by the Sydney University
Ethics Committee, Australia. The Sydney South West Area
Health Service Ethics Research Committee (RPAH Zone) was
also notiﬁed and endorsed the study.
Subjects
All subjects for the study were recruited from an ongoing
cohort of HIV-infected individuals at the HOP within the
Alto Mae ´ Health Centre in Maputo City, Mozambique.
Patients are referred to this HOP from a voluntary counselling
and testing (VCT) service located within the same Health
Centre. This VCT service is one of many institutions offering
free of charge HIV diagnosis for the public in Maputo City.
Informed consent to participate in the study was requested
from all consecutive patients coming to the HOP for routine
HIV-related clinical care visits in the period between 13
March and 2 June 2006. Exclusion criteria were present or
past history of ARV therapy, age less than 18 years, current
pregnancy, and those who declined to participate or were
unable to give informed consent.
Demographic, clinical and laboratory data
All consenting patients eligible for the study gave 5mL of
venous blood at the ﬁrst visit. This specimen was used to deter-
mine HTLV-1 status. Two weeks after the ﬁrst visit, patients
returned to collect their HTLV-1 test result. At this time, each
patient with a positive HTLV-1 result (case) was matched
with two patients with negative HTLV-1 results (controls) for
further study. The matching was performed based on World
Health Organization (WHO) clinical staging system for HIV,
age (+5 years) and gender. For cases for which there were
more than two possible controls, the two closest in age to the
case were selected. The selection of controls was made
without prior knowledge of full blood counts or CD4þ T-cell
counts results.
The researcher using a structured questionnaire then inter-
viewed cases and controls. The questionnaire included: sociode-
mographic data, sexual/reproductive history and clinical data.
General physical and neurological examination was performed
in all patients enrolled to assess patient status by WHO clinical
staging system for HIV and to stage HTLV-1 related diseases,
speciﬁcally the presence of neurological manifestations
23 and
skin lesions. To minimize the risk of recall bias caused by the
clinical researcher’s knowledge of HTLV-1 status, another
medical doctor who was blinded to HTLV-1 status conﬁrmed
all neurological signs and symptoms or skin lesions.
Agreement between the two doctors was taken as the deﬁnitive
ﬁnding. Finally, an additional 7mL of blood was drawn from
both cases and controls to perform T-cell subsets and
HIV-RNA viral load.
Laboratory assays
HIV serology
All patients enrolled in this study were tested for HIV 1/2 infec-
tion at the VCT services of the Health Centre. The national
algorithm for HIV diagnosis using the sequential testing with
two rapid assays was followed. All individuals were ﬁrst
screened using the Determine HIV-1/2 test (Abbott
Laboratories, Tokyo, Japan). Individuals whose specimens
were reactive on the screening assay were further tested using
the Uni-Gold HIV test (Trinity Biotech, Ireland). We did not
perform laboratory assays to discriminate infections with
HIV-1 from those with HIV-2 as HIV-1 is known to cause
more than 99% of HIV infections in Mozambique (Source of
information: Ministry of Health, Mozambique).
HTLV serology
Blood samples were screened for HTLV-1 using an immunoen-
zymatic qualitative test, Murex HTLV-1 þ 2 (Murex Biotech
Limited, Dartford, UK). Samples with reactive results were
further tested using a Western blot, HTLV BLOT 2.4
(Genelabs
w Diagnostics, Geneva, Switzerland). All patients
reactive to antigens codiﬁed by the GAG gene (p19 with or
without p24) and to two antigens encoded by the ENV gene
(GD21 and rgp46-I) were considered as positive for HTLV-1.
T-cell subsets immunophenotyping
Immunophenotyping was performed on fresh whole blood
using a FACSCaliburTM ﬂow cytometer (Becton Dickinson,
USA). MultiTEST reagents, TruCOUNT tubes and MultiTEST
software (all from Becton Dickinson, California, USA) were
used in a lyse-no wash protocol to determine absolute and per-
centage values for T-cell subsets (CD4þ T-cells, CD8þ T-cells
and CD4þ T/CD8þ T ratio).
HIV-RNA viral load
Plasma samples were stored at 270ºC until viral load was
assayed on a COBAS
w TaqMan 48 analyser (Roche
Diagnostics, Penzburg, Germany) for automated ampliﬁcation
and detection of nucleic acid. HIV-1 viral load was determined
using the COBAS
w TaqManTM HIV-1 test, for use with the
High Pure System (all from Roche Diagnostics, Germany). This
assay can quantify HIV-1 RNA over a range of 40–10,000,000
copies/mL.
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Data were double entered in a Microsoft Ofﬁce Access 2003
database by two independent data monitors. Accuracy of
data was compared using Epi Info Version 3.3.2. All data
were exported to be analysed in Stata software (StataCorp
2005. Stata Statistical Software: Release 9.0, College Station,
TX, USA).
Descriptive statistics was used to describe demographics and
medical history. To test signiﬁcance of the difference between
cases and controls with respect to baseline demographic charac-
teristics, sexual/reproductive history, clinical and laboratory
parameters, Pearson’s x
2, Fisher’s exact test and Mann-Whitney
U test were used, as appropriate. Correlation between CD4þ
T-cell counts and HIV-RNA viral loads as well as correlation
between body mass index (BMI) and CD4þ T-cell count
among HTLV-1 subgroups in different HIV clinical stages were
tested with Spearman’s rank correlation coefﬁcient. The level
of statistical signiﬁcance was set at 0.05.
RESULTS
Demographic characteristics and clinical history
From 724 HIV 1/2- infected patients invited to participate, 704
(97.4%) consented to be screened for HTLV-1 infection. HTLV-1
infection was identiﬁed in 32/704 patients (4.5%, 95% CI 3.0–
6.0). Three patients with a positive HTLV-1 antibody test did
not return to collect their result and were excluded from the
study. Sexual history, clinical presentation and laboratory ﬁnd-
ings were compared between 29 HIV/HTLV-1 dually infected
patients and 59 matched patients who were HIV-positive but
HTLV-1 negative.
Co-infected and mono-infected patients were comparable
with respect to demographic characteristics as well as sexual
and reproductive history (Table 1). The median age was 40
years (intraquartile range [IQR] 34.0–48.0) versus 41 years
(IQR 32.0–47.0) for co-infected and mono-infected patients,
respectively. No patient had a past history of injecting intrave-
nous drugs. However, a previous blood transfusion was
reported by 6/29 (20.7%, 95% CI 0.059–0.354) co-infected
patients and by 14/59 (23.7%, 95% CI 0.128–0.346) mono-
infected patients (P ¼ 0.75). History of scariﬁcation was
reported by 22/29 (75.9%, 95% CI 0.603–0.915) and by 41/59
(69.5%, 95% CI 0.578–0.812) individuals in the co-infected
and mono-infected group, respectively (P ¼ 0.54). Clinical epi-
sodes of sexually transmitted infections (STIs) were reported
by 12/29 (41.4%, 95% CI 0.235–0.593) of co-infected patients
and by 27/59 (45.8%, 95% CI 0.331–0.585) of mono-infected
patients (P ¼ 0.70).
Clinical manifestations and HIV disease staging
Twenty-four (83.8%) patients with co-infection and 47 (79.7%)
with mono-infection were in stage I and II of HIV infection.
No patient had an AIDS deﬁning condition (Table 1). Median
BMI decreased in both groups with clinical progression of
HIV infection and it tended to be lower in co-infected patients
(21.79kg/m
2, 95% CI 18.64–26.05) compared with mono-
infected patients (23.95kg/m
2, 95% CI 21.34–27.97). However,
this difference was not statistically signiﬁcant (P ¼ 0.06).
The most common neurological manifestation in both groups
was sensory symptoms (tingling, pins, needles and burning
sensations), which was reported in 5/29 (17.2%, 95% CI
0.034–0.309) patients with co-infection and in 8/59 (13.6%,
95% CI 0.049–0.223) patients with mono-infection (P ¼ 0.65).
Two (6.9%, 95% CI 20.023–0.161) patients with HTLV-1 were
found to have hyperreﬂexia of lower limbs associated with
positive Babinski sign and clonus (P ¼ 0.11). Further neurologi-
cal investigation of these cases was not undertaken.
Skin lesions observed in co-infected and mono-infected
patients, respectively, included 6/29 (20.7%, 95% CI 0.059–
0.354) versus 20/59 (33.9%, 95% CI 0.218–0.460) with papular
pruritic eruption (P ¼ 0.20), 6/29 (20.7%, 95% CI 0.060–0.354)
versus 11/59 (18.6%, 95% CI 0.087–0.285) with
Table 1 Demographics, sexual history and clinical charac-
teristics of patients with HIV infection only and those with HIV
and HTLV-1
HIV–HTLV-1
co-infected
patients (n 5 29)
HIV mono-infected
patients (n 5 59)
P
values
Gender
Men 4 (14%) 8 (14%)
Women 25 (86%) 51 (86%) 0.98
Age (years)
Median 40.0 41.0 0.99
IQR 34.0–48.0 32.0–47.0
Range 20.0–65.0 18.0–60.0
Marital status 0.17
Single 5 (17%) 9 (15%)
Married 9 (31%) 31 (53%)
Widow 6 (21%) 11 (19%)
Divorced 9 (31%) 8 (14%)
Received blood
transfusion
6 (21%) 14 (24%) 0.75
History of
scariﬁcation
22 (76%) 41 (70%) 0.54
History of sexually
transmitted
history
12 (41%) 27 (46%) 0.70
Age of ﬁrst sexual
contact (years)
0.43
Median 17.0 17.0
IQR 15.5–19.0 16.0–19.0
Range 14.0–25.0 14.0–25.0
Number of sexual partners, median (IQR)
Last month 0 (0–1) 1 (0–1) 0.33
Last 3 months 0 (0–1) 1 (0–1) 0.98
Last 12 months 1 (0–1) 1 (0–1) 0.81
Lifetime 3 (2–4) 3 (2–4) 0.86
Number of
pregnancies
0.41
Median (IQR) 4 (2–7) 5 (3–7)
Number of
children
0.45
Median (IQR) 3 (1–4) 3 (1–5)
Number of
miscarriages
0.39
Median (IQR) 2 (1–3) 2 (1–2)
Body mass index
(kg/m
2)
0.06
Median 21.79 23.95
IQR 18.64–26.05 21.34–27.97
Range 15.24–33.98 14.60–36.91
HIV clinical stage
(WHO)
0.94
I 7 (24%) 14 (23%)
II 17 (59%) 33 (56%)
III 5 (17%) 12 (21%)
IV 0 0
HTLV-1¼ human T-cell lymphotropic virus; HIV¼ human immunodeﬁciency virus;
IQR ¼ intraquartile range; WHO ¼ World Health Organization
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0.264) versus 6/59 (10.2%, 95% CI 0.025–0.179) with evidence
of past herpes zoster (P ¼ 0.62). None of the co-infected patients
presented with erythema palmare and cutaneous candidiasis,
while 1/29 (3.4%) case of each occurred in mono-infected
patients (P ¼ 0.67).
Lymphocyte proﬁles
Co-infected patients had higher median of total leukocytes
count, higher CD4þ T-cell (absolute/percent) count, lower
CD8þ T-cell percent count and higher CD4þ T/CD8þ T ratio
(Table 2). Among co-infected patients, the median CD4þ
T-cell absolute count was 525 cells/mm
3 (IQR 310–827) com-
pared with 274 cells/mm
3 (IQR 183–436) in mono-infected
patients (P ¼ 0.001). Furthermore, 25/29 (86.2%, 95% CI
0.736–0.988) of co-infected patients had a CD4þ T-cell count
greater than 200 cell/mm
3 compared with 41/59 (69.5%, v
0.578–0.812) patients with mono-infection (matched OR ¼
2.74, 95% CI 0.81–9.29). Co-infected patients were 7.2 times
(95% CI 1.59–32.51) more likely to have a CD4þ T-cell count
above 500 cells/mm
3 (Table 3).
Analysis of the relationship between CD4þ T-cell count and
HIV clinical stage (Figure 1) demonstrated that in patients with
mono-infection, CD4þ T-cells counts were signiﬁcantly lower
in groups with evidence of clinical progression of HIV infection
(95% CI 20.59 to 20.15, P ¼ 0.0024). In contrast, in patients
with co-infection, CD4þ T-cells counts did not decrease with
progression of HIV infection (95% CI 20.34 to 0.39, P ¼ 0.8926).
HIV-1 viral load
The median HIV RNA viral load was 56,385 copies/mL (IQR
14,749–277,557) in co-infected patients compared with 37,573
copies/mL (IQR 11,322–176,837) in mono-infected patients
(P ¼ 0.36). In both groups, the HIV-RNA load tended to
increase with clinical progression of HIV infection (Figure 2).
However, a statistically signiﬁcant increase of HIV-RNA viral
load by HIV clinical stage was only observed in patients with
co-infection (P ¼ 0.04 versus P ¼ 0.10).
As expected, we documented a strong inverse relationship
between levels of HIV-RNA and absolute CD4þ T-cell counts
in mono-infected patients (95% CI 20.73 to 20.38, P,
0.0001). However, of importance, a similar relationship was
not observed in patients with HIV/HTLV-1 co-infection (95%
CI 20.60 to 0.07, P ¼ 0.11).
DISCUSSION
The prevalence of HTLV-1 infection is known to vary from
region to region. However, in the same geographical region, it
can vary in different population subgroups, probably reﬂecting
the diverse modes of its transmission.
24 The overall prevalence
of anti-HTLV-1 antibodies among HIV positive patients found
Table 2 Laboratory characteristics of patients with HIV
infection only and those with HIV and HTLV-1
HIV–HTLV-1
co-infected
patients
(n 5 29)
HIV
mono-infected
patients
(n 5 59) P values
Total leukocytes
(10
3/mm
3)
0.04
Median 4.4 3.9
IQR 3.9–5.7 3.1–4.9
Range 2.69–12.98 2.03–8.14
Total lymphocytes
(10
3 cells/mm
3)
0.15
Median 1.78 1.54
IQR 1.28–1.94 1.38–2.26
Range 0.64–4.52 0.62–3.95
CD41 T-cell count
(cells/mm
3)
0.001
Median 525 274
IQR 310–827 183–436
Range 62–3363 35–986
CD41 T-cell count (%) ,0.001
Median 24.86 15.86
IQR 18.97–32.73 9.37–21.03
Range 7.57–65.42 2.41–38.00
CD81 T-cell count
(cells/mm
3)
0.71
Median 1002 937
IQR 649–1090 666–1358
Range 325–2876 234–2851
CD81T-cell count (%) 0.01
Median 46.83 54.17
IQR 36.23–53 42.71–61.34
Range 21.21–70.78 28.83–85.70
CD41 T/CD8 1 T ratio ,0.001
Median 0.48 0.31
IQR 0.34–0.82 0.16–0.43
Range 0.12–3.09 1.22–0.03
HIV-RNA viral load
(copies/mL)
0.36
Median 56,385 37,573
IQR 14,749–
277,557
11,322–
176,837
Range 0–743,253 78–4,805,932
HTLV-1¼ human T-cell lymphotropic virus; HIV¼ human immunodeﬁciency virus;
IQR ¼ intraquartile range
Table 3 Odds ratio of CD4þ T-cell count strata in patients with HIV infection and those with HIV and HTLV-1
Characteristics
HIV–HTLV-1 co-infected patients
(n 5 29)
HIV mono-infected patients
(n 5 59) Odds ratio (95% CI) P value
CD41 T-cell count (cells/mm
3) 0.001
,200 4 (14%) 18 (31%) 1
200–500 9 (31%) 31 (52%) 1.31 (0.35–4.9)
.500 16 (55%) 10 (17%) 7.2 (1.59–32.51)
CD41 T-cell count (%) ,0.001
,15 5 (17%) 24 (41%) 1
15–20 4 (14%) 16 (27%) 1.2 (0.28–5.25)
.20 20 (69%) 19 (32%) 5.05 (1.47–17.40)
HTLV-1, human T-cell lymphotropic virus; HIV¼ human immunodeﬁciency virus; CI ¼ conﬁdence interval
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African blood donors.
9,25,26 This would be consistent with
those subjects with HIV also being at increased behavioral
risk for acquiring HTLV-1 infection as both viruses have the
same routes of transmission. However, it could equally be con-
sistent with widespread epidemics of HIV and HTLV-1 running
in parallel but with different transmissibility parameters.
In some countries with a high prevalence of intravenous drug
use (IDU), the prevalence of HTLV-1 infection is considerably
higher.
27 In our study, we did not report any case of IDU. It
has been estimated that 80–90% of HIV infections in the devel-
oping world are due to heterosexual transmission.
28,29 It is most
likely that, in our setting, the major form of horizontal trans-
mission of HTLV-1 is through heterosexual intercourse.
However, it may also possible that the transmission of retro-
viruses through needles and surgical instruments at health
facilities or at traditional healing practices play a relevant epide-
miological role.
As already reported in other geographical regions and
diverse populations,
19,20,22,27,30,31 Mozambican patients
co-infected with HTLV-1 displayed higher CD4þ T-cell
counts when compared with mono-infected patients matched
for clinical stage of HIV disease. We could not investigate the
relationship between HTLV-1 infection and HIV disease pro-
gression in individual patients due to the cross-sectional
design of our study.
Nevertheless, it was evident that BMI decreased with clinical
progression of HIV infection in all patients. This suggests that
HIV disease progression also leads to clinical deterioration of
co-infected patients. In fact, BMI was generally lower in
co-infected patients, although this was shown not to be statisti-
cally signiﬁcant (P ¼ 0.06). We did not ﬁnd any statistical differ-
ence comparing demographic, sexual and reproductive
characteristics between cases and controls, which makes it
less likely that the high CD4þ T-cell counts found in co-infected
patients were biased by the difference in duration of HIV infec-
tion. Incidental to the primary goals of this study, we looked at
clinical features in major organ systems but could not associate
any neurological symptoms or skin lesions with HTLV-1 infec-
tion, probably due to the small number of patients enrolled in
the study.
In southern Africa, patients showing CD4þ T lymphocyte
counts that do not reﬂect their HIV clinical staging should
be suspected as having HTLV-1 infection. In our study, 60.0%
(3/5) of co-infected patients with HIV clinical stage III had
an absolute CD4þ T-cell count above 350 cells/mm
3.
In co-infected patients, CD4þ T lymphocyte counts are not
reliable markers to guide initiation of prophylaxis against
opportunistic infections or HAART. The current general
recommendations to start HAART in resource poor settings
are based on the combined use of HIV clinical staging and
the CD4þ T-cells count. An exception is considered for patients
with chronic HIV infection who have CD4þ T-cell counts
between 201–350 cell/mm
3, in whom HAART can be started
when HIV-RNA viral load levels indicate signiﬁcant risk of
progression.
23
This study suggests that HIV-RNA viral load increases mark-
edly with clinical progression of HIV-HTLV co-infected patients
(Figure 2). Therefore, HIV-RNAviral load might give important
additional information about the true risk of early progression
to more advanced clinical stages in these patients. Additionally,
HIV viral load is also likely to be a much more reliable guide to
determining intervention points with ARV in HIV-HTLV
co-infected subjects.
Our results support the hypothesis that, in HIV/HTLV-1
co-infected patients, the dissociation between clinical and
immunological markers derive from a loss of the inverse corre-
lation between the HIV viral load and the CD4þ T-cell count as
a direct result of HTLV-1 infection. This study did not address
the molecular basis of the protection of CD4 T-cells from rapid
decline in association with HIV viraemia but it provides
a strong rationale for such future studies. Our results are of
particular relevance for care/treatment scale-up programmes
in sub-Saharan Africa, where CD4þ T lymphocyte counts
constitute the main laboratory parameter used for checking
HIV disease progression as well as guiding HAART initiation
and monitoring. The small number of our sample size, the
Figure 1 CD4þ T-cell counts (cell/mm
3) distribution in HIV mono-
infected patients and HIV/HTLV-1 co-infected patients according
to HIV clinical stage. HTLV 12, HIV-infected patients; HTLV 1þ,
HIV-infected patients co-infected with HTLV-1. I, HIV clinical
stage 1; II, HIV clinical stage 2; III, HIV clinical stage
3. Mono-infection is infection with HIV only; co-infection is infec-
tion with HTLV-1 and HIV
Figure 2 HIV-RNA viral load (copies/mL) distribution in HIV mono-
infected patients and HIV/HTLV-1 co-infected patients according
to HIV clinical stage. HTLV 12, HIV-infected patients; HTLV 1þ,
HIV-infected patients co-infected with HTLV-1. I, HIV clinical
stage 1; II, HIV clinical stage 2; III, HIV clinical stage
3. Mono-infection is infection with HIV only; co-infection is infec-
tion with HTLV-1 and HIV
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lation and the low numbers of patients on WHO stage III of
HIV infection constitute limitations of this study. These limit-
ations, together with the cross-sectional nature of the study,
did not allow us to deﬁne the impact of co-infection on HIV
disease progression.
Despite its limitations, this study does not support the use in
HTLV-1 co-infected patients of current recommendations for
initiation of ART and chemoprophylaxis against opportunistic
infections according to CD4þ T-cell counts. Thus, in settings
with a high prevalence of HTLV-1 infection among the HIV-1
infected population, serological testing for HTLV-1 should
ideally be available so that HIV viral load might be integrated
into the treatment initiation algorithm. Deﬁning appropriate
thresholds of HIV viral load relevant to intervention points
for co-infected patients will require longitudinal studies.
In the short term, it is unlikely that overburdened health
systems in sub-Saharan Africa will be able to routinely test
for HTLV-1 infection and/or HIV viral load. Therefore, in
patients with dissociation between clinical and immunological
parameters, the WHO clinical staging system, with minimal
weight placed on CD4 T-cell data, should be recommended to
monitor progression of HIV infection and guide initiation of
therapy.
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